CNS Pharmaceuticals (CNSP) investor relations material

Company overview and strategy

• Specializes in neuro-oncology, focusing on primary and metastatic brain cancers with drugs that cross the blood-brain barrier.

• Maintains a strong financial position with over $12 million in cash as of Q2, extending into the second half of 2026.

• Operates a global clinical development network, enabling efficient trial execution and rapid clinic re-entry.

• Focuses on tried and true drug classes, making mechanisms familiar to clinicians and regulators.

• Plans to expand from primary brain cancer to metastatic brain disease markets.

Lead compound: TPI 287

• TPI 287 is a late-stage, blood-brain barrier-penetrant taxane designed for glioblastoma multiforme (GBM).

• Demonstrates significant brain penetration and efficacy in animal and human studies.

• In combination with bevacizumab, extends median overall survival to 13.4 months for second-line GBM, compared to 6–8 months standard.

• Shows multiple durable complete and partial responses, with a strong safety profile.

• Phase II study planned for the first half of next year.

Second compound: Berubicin

• Berubicin is a novel, blood-brain barrier-penetrant anthracycline for GBM.

• Recent pivotal study showed similar overall survival to Lomustine, not meeting the primary endpoint.

• Clinically relevant as a potential third-line therapy, offering a mechanistically distinct option.

• Demonstrates no cardiotoxicity in long-term patients, a potential breakthrough for anthracyclines.

• Ongoing regulatory and strategic evaluations, with optimism for future pathways.